With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Single-dose administration of E6F6 could profoundly suppress the levels of hepatitis B surface antigen (HBsAg ... E6F6 recognises an evolutionarily conserved epitope (GPCK(R)TCT) and only forms a ...

in particular hepatitis B surface-specific T cell responses. HBV-specific CD8 + T cells with different target specificities (HBV core epitope vs HBV polymerase (pol) epitope) are characterised by ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in ... or HBV core antibody (anti-HBc). The most common cause of HBVr is prolonged ...

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

For patients at high risk of hepatitis B reactivation, AGA recommends preventive antiviral medication. Reactivated HBV can lead to liver damage, hospitalization, and even death.

In this manuscript, the authors describe a new AlphaFold2 pipeline called PabFold that can represent a useful tool for identifying linear antibody epitopes (B-cell epitopes ... binding an epitope in ...

About ICP-B02 (CM355) ICP-B02 is a CD20×CD3 bispecific antibody jointly developed by InnoCare ... and diffuse large B-cell lymphoma (DLBCL). Based on the encouraging results of ICP-B02 single ...

This manuscript describes a method using EM polyclonal epitope ... antibody sequences from cryoEM data with ModelAngelo. A) Exemplary map (with top10% alignment scores of 1076/1174 for HC/LC) from the ...

Discussion: These findings demonstrate the potential of the immunoinformatics-designed multi-epitope vaccines for ... that bind selectively to the B-cell receptor (BCR), thereby activating B-cells and ...